RARA: A Protein with Potential as A Drug Target Or Biomarker (G5914)

Target Name: RARA

NCBI ID: G5914

RARA

RARA: A Protein with Potential as A Drug Target Or Biomarker

RARA (RARA variant 1) is a protein that is expressed in various tissues of the body, including the brain, heart, and kidneys. It is a key regulator of cell survival and growth, and is involved in many important cellular processes. In recent years, researchers have become increasingly interested in RARA as a potential drug target or biomarker, due to its unique biology and the potential it holds for the development of new therapies.

History of RARA

The RARA gene was first identified in the late 1980s as a gene that encodes a protein with 115 amino acid residues. The protein encoded by this gene is highly conserved across various species, and is highly expressed in many tissues of the body. RARA has been implicated in many important cellular processes, including cell survival, growth, and angiogenesis.

Expression of RARA

RARA is highly expressed in a wide variety of tissues, including the brain, heart, and kidneys. It is expressed in the brain, where it is involved in the regulation of neural cell survival and growth. RARA is also expressed in the heart, where it is involved in the regulation of cardiac cell survival and contractility. Additionally, RARA is expressed in the kidneys, where it is involved in the regulation of kidney cell survival and function.

Drug Target Potential

RARA has been identified as a potential drug target due to its unique biology and the potential it holds for the development of new therapies. One of the key reasons for its potential as a drug target is its conserved nature. This makes it easier to identify potential drug targets, as well as to develop new treatments that target specific RARA variants.

Another reason for RARA's potential as a drug target is its involvement in many important cellular processes. As mentioned earlier, RARA is involved in the regulation of cell survival, growth, and angiogenesis. This makes it an attractive target for drugs that aim to treat a range of diseases, including cancer, neurodegenerative diseases, and cardiovascular diseases.

RARA also has a unique mechanism of action that makes it an attractive target for drugs. Unlike many other proteins, RARA does not have a primary structure, which makes it difficult to predict its behavior. This lack of predictability makes it more difficult for enemies to target RARA, as they cannot predict its movements.

Biomarker Potential

RARA has also been identified as a potential biomarker for a range of diseases. Its unique biology and the potential it holds for the development of new therapies make it an attractive target for biomarkers. For example, RARA has been used as a biomarker for cancer, neurodegenerative diseases, and cardiovascular diseases.

Conclusion

In conclusion, RARA is a protein that has garnered significant interest due to its unique biology and the potential it holds for the development of new therapies. Its conserved nature and involvement in many important cellular processes make it an attractive target for drugs, as well as for the development of biomarkers. Further research is needed to fully understand the biology and potential of RARA, and to develop new treatments that target this protein.

Protein Name: Retinoic Acid Receptor Alpha

Functions: Receptor for retinoic acid (PubMed:19850744, PubMed:16417524, PubMed:20215566). Retinoic acid receptors bind as heterodimers to their target response elements in response to their ligands, all-trans or 9-cis retinoic acid, and regulate gene expression in various biological processes (PubMed:28167758). The RXR/RAR heterodimers bind to the retinoic acid response elements (RARE) composed of tandem 5'-AGGTCA-3' sites known as DR1-DR5 (PubMed:28167758, PubMed:19398580). In the absence of ligand, the RXR-RAR heterodimers associate with a multiprotein complex containing transcription corepressors that induce histone deacetylation, chromatin condensation and transcriptional suppression (PubMed:16417524). On ligand binding, the corepressors dissociate from the receptors and associate with the coactivators leading to transcriptional activation (PubMed:9267036, PubMed:19850744, PubMed:20215566). Formation of a complex with histone deacetylases might lead to inhibition of RARE DNA element binding and to transcriptional repression (PubMed:28167758). Transcriptional activation and RARE DNA element binding might be supported by the transcription factor KLF2 (PubMed:28167758). RARA plays an essential role in the regulation of retinoic acid-induced germ cell development during spermatogenesis (By similarity). Has a role in the survival of early spermatocytes at the beginning prophase of meiosis (By similarity). In Sertoli cells, may promote the survival and development of early meiotic prophase spermatocytes (By similarity). In concert with RARG, required for skeletal growth, matrix homeostasis and growth plate function (By similarity). Together with RXRA, positively regulates microRNA-10a expression, thereby inhibiting the GATA6/VCAM1 signaling response to pulsatile shear stress in vascular endothelial cells (PubMed:28167758). In association with HDAC3, HDAC5 and HDAC7 corepressors, plays a role in the repression of microRNA-10a and thereby promotes the inflammatory response (PubMed:28167758)

The "RARA Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about RARA comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets